Summary

Prolonged release (PR)-fampridine treatment resulted in sustained and clinically meaningful improvement in walking ability and balance throughout a 6-month treatment period in individuals with multiple sclerosis (MS). The Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis study [MOBILE; NCT01597297; Hupperts R et al. ACTRIMS/ECTRIMS 2014 (poster P922)] evaluated the effect of PR-fampridine on walking ability, dynamic and static balance, and subjective impressions of well-being.